Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Market Cap	153.00B +16.8%
Revenue (ttm)	264.10B +10.7%
Net Income	182.29M -96.1%
EPS	8.00 -95.9%
Shares Out	23.91M
PE Ratio	839.32
Forward PE	n/a
Dividend	50.00 (0.78%)
Ex-Dividend Date	Dec 29, 2025

Volume	68,539
Average Volume	129,585
Open	6,350.00
Previous Close	6,400.00
Day's Range	6,080.00 - 6,450.00
52-Week Range	4,755.00 - 9,300.00
Beta	0.37
RSI	41.30
Earnings Date	n/a

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 214390

Financial Performance

In 2025, Kyongbo Pharmaceutical's revenue was 264.10 billion, an increase of 10.71% compared to the previous year's 238.56 billion. Earnings were 182.29 million, a decrease of -96.07%.